From the Journals

New Score Assesses Epilepsy Risk Post-CVT

With DIAS3 predicting epilepsy risk post-CVT from as low as 7% to 83% over three years, doctors can tailor ASM strategies based on a patient’s individual profile—advancing precision in CVT care.

Share

  • 1

    The DIAS3 score predicts epilepsy risk post-cerebral venous thrombosis, estimating from 7% to 83% over three years.

  • 2

    It is based on a cohort study spanning multiple countries and includes six clinical variables.

  • 3

    Published in JAMA Neurology, the model's discriminative ability was strong, with good calibration.

  • 4

    Key predictors in the DIAS3 score include age, decompressive hemicraniectomy, acute-phase seizures, and subdural hematoma.

  • 5

    The score may guide antiseizure medication decisions and identifies patients who may not require prolonged treatment.

  • 6

    Limitations of the study include retrospective data components and absent three-year validation for Israel CVT.

  • 7

    The DIAS3 calculator is accessible online for individualized risk assessment in cerebral venous thrombosis care.

Original Source(s)

New Score Assesses Epilepsy Risk Post-CVT

With DIAS3 predicting epilepsy risk post-CVT from as low as 7% to 83% over three years, doctors can tailor ASM strategies based on a patient’s individual profile—advancing precision in CVT care.

  • by Kathryn Wighton

  • November 4, 2024

  • 2 min

Related Content

Cenobamate Shows Stronger Real-World Seizure Control

Large retrospective analysis highlights differences in seizure control, retention, and adverse effects among newer agents

Epilepsy Linked to Heart Risks in Seniors

Brain Cell Networks Mapped with CRISPR

A new Perturb-seq platform utilizes adeno-associated viruses vectors and transposons to examine cell-specific transcriptional networks within the developing brain in vivo.